VivoSeq
Immunology

Graft Versus Host Disease

89

Pipeline Programs↗

21

Active Trials↗

41

Companies Involved↗

Graft Versus Host Disease is a moderately active landscape with 89 programs across 41 companies. The most active players are Gilead, Glaxo Dba Glaxosmithkline, Avyxa. 24 therapies are approved with 14 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

69/100

Pipeline Velocity

22/100

Mech. Concentration

11/100

Completion Rate

67/100

Attrition Rate

21/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Gilead logo

Gilead

1 program

Phase 1G

Glaxo Dba Glaxosmithkline

1 program

Phase 1A

Avyxa

1 program

Phase 1A

Arog Pharmaceuticals, Inc.

1 program

Phase 1G

Genzyme, a Sanofi Company

2 programs

Phase 2R

Rigel Pharmaceuticals

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical6

Romidepsin

Teva

Efalizumab

Roche

Telmisartan

Boehringer Ingelheim

Maat013

MaaT Pharma

Cryopreservation

Central Hospital, Nancy, France

Phase 117

Belimumab

Glaxo Dba Glaxosmithkline

Cannabidiol

Jazz Pharmaceuticals

Palifermin

Swedish Orphan Biovitrum

Methylprednisolone Sodium Succinate

Massachusetts Eye and Ear Infirmary

Voriconazole

Prism Pharmaceuticals

Phase 228

Aldesleukin

Iovance Biotherapeutics, Inc.

Abatacept

Bristol-Myers Squibb

Brentuximab Vedotin

Pfizer

Mycophenolate Mofetil

Roche

Obinutuzumab

Roche

Phase 314

Itacitinib

Incyte

Infliximab

Organon and Co

Mycophenolic Acid

Novartis

Daclizumab

Roche

Iguratimod

Jiangsu Simcere Pharmaceutical Co., Ltd.

Approved24

Methotrexate

Alnylam Pharmaceuticals

Pentostatin

Pfizer

Belumosudil

Kadmon, a Sanofi Company

Letermovir

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Panobinostat

SecuraBio

Analysis

Modality Breakdown

71%

Small molecule

67 of 94 classified programs — the dominant modality here.

29%ALL OTHERSMonoclonal antibody1314%Protein / enzyme89%Cell therapy33%Peptide22%Antibody–drug conjugate11%

Small molecule leads; the ring shows all 94 classified programs, each share of the total. Modality classified for 99% of 104 pipeline programs.

Analysis

Trial Status

103

clinical trials

Completed45 · 44%
Terminated17 · 17%
Unknown status13 · 13%
Recruiting12 · 12%
Withdrawn5 · 5%
Active, not recruiting5 · 5%
Other6 · 6%

Clinical Trials

Trial Activity

103 trials

Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation
Recruiting·SShanghai Jiao Tong University School of Medicine·Phase 3·NCT06705062·316 enrolled
Tissue Immune Landscape of Graft Versus Host Disease After Allogeneic Stem Cell Transplantation (TIL-GVHD)
Recruiting·UUniversity Hospital, Bordeaux·N/A·NCT06247150·70 enrolled
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT03970096·120 enrolled
Fecal Microbiota Transplant and Dietary Fiber Supplementation for the Treatment of Gut Graft Versus Host Disease
Recruiting·FFred Hutchinson Cancer Center·Phase 1·NCT05067595·72 enrolled
Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis
Recruiting·—·Phase 2·NCT04380740·160 enrolled
A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CROSSOVER STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 μG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)
Recruiting·LLubris Bio Pty Ltd·Phase 2·NCT07118254·15 enrolled
Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease )
Recruiting·—·Phase 2·NCT07340723·168 enrolled
A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06973668·80 enrolled
PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis
Recruiting·HHenry Ford Health System·Phase 1·NCT04886726·18 enrolled
A Randomized, Open-Label, Parallel-Controlled, Multicenter Phase III Clinical Trial of Anti-CD25 Monoclonal Antibody Versus Methotrexate for the Prevention of Acute Graft-Versus-Host Disease After Haploidentical Hematopoietic Stem Cell Transplantation
Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 3·NCT07689630·186 enrolled
Use of Granulocyte Colony Stimulating Factor (G-CSF) Mobilized Leukapheresis Collections From Healthy Volunteers to Develop Improved Methods of Stem Cell and Lymphocyte Selection for Allogeneic Transplantation
Recruiting·National Heart, Lung, and Blood Institute (NHLBI)·N/A·NCT00001529·500 enrolled
Phase II Open Label Prospective Nonrandomized Trial of Belumosudil for Switch-Maintenance Prophylaxis of Graft-versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT07006506·46 enrolled
A Randomized Phase II Study to Compare the Potential Long-Lasting Positive Effect of Decidual Stromal Cells to the Best Available Treatment in Graft Versus Host Disease
Active, not recruiting·UUniversity Health Network, Toronto·Phase 2·NCT05132166·50 enrolled
Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants
Active, not recruiting·—·Phase 2·NCT05364762·20 enrolled
De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis
Active, not recruiting·MMedical College of Wisconsin·Phase 2·NCT05622318·56 enrolled
Page 1 of 7

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)